Klick Health Continues Creative Hiring Spree
Klick Health announced the addition of more accomplished Creative trailblazers to its team as the independent agency continues to experience record-breaking growth.
About Andrew Humphreys
This author has not written his bio yet.
But we are proud to say that Andrew Humphreys contributed 3897 entries already.
Entries by Andrew Humphreys
FDA bars critic from review panel of Biogen’s controversial Alzheimer’s drug
The U.S. Food and Drug Administration, citing conflict of interest, recused a member of an 11-person advisory committee set to review Biogen Inc.’s experimental Alzheimer’s drug aducanumab.
Santhera Slashes Workforce in Half After Phase III DMD Failure
Less than a month after the failure of a Phase III Duchenne muscular dystrophy (DMD) trial, Switzerland-based Santhera Pharmaceuticals announced a corporate restructuring that includes the termination of 50 percent of the company’s workforce.
Leaders face ‘critical moment’ as Covid cases spike, says WHO chief
World Health Organization Director-General Tedros Adhanom Ghebreyesus said a recent spike in Covid-19 cases in some countries in Europe and North America presented leaders with a “critical moment for action.”
Election Implications for the U.S. and Global Covid-19 Response
The aftershocks of the 2020 U.S. presidential election will be felt from the top-down at the Department of Health and Human Services (HHS) and beyond.
Sanofi Picks Up Kiadis for $359 Million
Paris-based Sanofi and Amsterdam-based Kiadis Pharma inked a deal for Sanofi to acquire the entire share capital of Kiadis.
T-cell study adds to debate over duration of Covid-19 immunity
A small but key UK study found that “cellular immunity” to the pandemic SARS-CoV-2 virus is present after six months in people who had mild or asymptomatic Covid-19, suggesting they might have some level of protection for at least that time.
CureVac’s Covid-19 vaccine triggers immune response
CureVac’s experimental Covid-19 vaccine triggered an immune response in humans, putting the German biotech firm on track to start mass testing during 2020 as the race to end the pandemic heats up.
Japan’s Sosei allies with ex-Novartis team to develop neurological drug pipeline
Japan’s Sosei Group Corp. is allying with a U.S. biotech run by former Novartis AG executives to commercialize a neurological drug pipeline.
U.S. coronavirus cases keep rising in grim march to Election Day
Coronavirus cases continued their grim climb in the United States with Midwestern states experiencing record hospitalizations, as increasingly bitter rhetoric kept the virus front and center of campaigning two days before the presidential election.
